Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

ASSOCIATION OF COMMUNITY CANCER CENTERS ONCOLOGIC INTRAVENOUS AND ORAL COMBINATION REGIMENS STRATEGIES FOR CARE COORDINATION Effective Practices Publication TABLE OF CONTENTS Introduction .....................................................................................................2 Top Challenges …
TENNESSEE ONCOLOGY PRACTICE SOCIETY (TOPS) MEMBERS ENJOY A 50% DISCOUNT WHEN REGISTERING ONLINE REGISTER TODAY! USE DISCOUNT CODE DURING REGISTRATION: TOPS50 info@meccinc.com | 305.663.1628 | meccinc.com
Rockville, MD—The Association of Community Cancer Centers (ACCC) announced today that Ochsner Cancer Institute in New Orleans, La., is a recipient of a 2022 ACCC Innovator Award. The award recognizes Ochsner Cancer Institute’s Chemotherapy Care Companion program—a digital technology system that allows the cancer care team to remotely monitor patients who are on intravenous or oral anti-cancer treatment …
Since implementation, Chemotherapy Care Companion has decreased patients’ healthcare costs by preventing emergency department (ED) visits and hospitalizations and improved their overall satisfaction.
iNNOVATiON DECONSTRUCTING SPONSORSHIP & EXHIBIT PROSPECTUS ACCC n n n n n Palm Beach Palm Beach Convention CenterConvention Center October 12–14, 2022 39TH NATIONAL ONCOLOGY CONFERENCE ONCOLOGY CONFERENCE The ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC) invites you to become a sponsor for its 39th National Oncology Conference, October 12–14, 2022, at the Palm …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Hear how malnutrition affects people with cancer in different ways, even impacting cancer treatment plans.
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
ACCCBuzz spoke with Sanketh Andhavarapu, co-founder and chief of product and strategy, and Veeraj Shah, chief executive officer, to learn how Vitalize—a wellness-based platform—is addressing burnout among healthcare providers.
August 11, 2022
Learn about the key proposals in the CY 2023 Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules and how these proposed changes to Medicare payment will impact oncology practices, freestanding cancer centers, and hospital-based cancer programs in 2023. There will be an opportunity for live Q&A.Speakers: Teri Bedard, BA, RT(R)(T), CPCExecutive …
IMPORTANT PRESCRIBING INFORMATION Important Information for Lynparza (olaparib) for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy August 2022 Dear Healthcare Professional, This letter is to inform you of a potential detrimental effect on …
Rockville, MD – The Association of Community Cancer Centers (ACCC) today released the following statement of support for President Biden’s nomination of Monica Bertagnolli, MD, FACS, FASCO, as the new Director of the National Cancer Institute (NCI). “Dr. Bertagnolli has the talent, skill and commitment to excellence required to lead the nation’s professional oncology community in its aggressive pursuit …
Overview of Billing & Coding for Cancer Drugs For Internal Use Only Overview of Billing & Coding for Cancer Drugs Confidential--For Internal Use Only Disclaimer • CPT codes and descriptions only are copyright 2020 American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. • All Medicare information …
OPCC Legislative Update IOS Legislative Update August 12, 2022 About me • Regional Government Relations Director (IN, OH, MO, WI) • Based in Indianapolis • 8 years with ACS CAN • Prior: Grassroots organizing; Indiana senate staff; non-profit & political campaigns • No conflicts of interest to disclose in relation to this presentation Indiana’s Cancer Burden …
PowerPoint Presentation Practical Strategies to Avoid Burnout, and How to Help Build Resilience in Your Team Jennifer Bires, LCSW, OSW-C Executive Director Life with Cancer and Patient Experience How to keep walking forward, and even find renewal along the way, in this year of things blown apart? What sustains us? How to hold on to our sense of what …
Hear about a treatment plan collaboration between the oncology care team and PCP from one of our 2022 ACCC Innovator Award winners—ChristianaCare's Helen F. Graham Cancer Center & Research Institute.
August 9, 2022
Multiple studies have shown that integrating remote symptom monitoring into cancer care using patient-reported outcomes (PRO) favorably impacts quality of life, healthcare utilization, and overall survival in patients with cancer. However patient adherence with remote PROs outside of a clinical trial is widely variable. With the integration of technology into cancer care and the rapid adoption …